SAB Biotherapeutics (NASDAQ:SABS) Rating Reiterated by Chardan Capital
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reissued by Chardan Capital in a note issued to investors on Tuesday, Benzinga reports. They presently have a $25.00 price target on the stock. Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in […]
More Stories
Short Interest in Cineverse Corp. (NASDAQ:CNVS) Expands By 44.3%
Cineverse Corp. (NASDAQ:CNVS – Get Free Report) was the recipient of a large increase in short interest during the month...
China Railway Group Limited (OTCMKTS:CRWOF) Short Interest Update
China Railway Group Limited (OTCMKTS:CRWOF – Get Free Report) was the recipient of a large increase in short interest during...
Short Interest in BlackRock Short-Term California Muni Bond ETF (NASDAQ:CALY) Expands By 45.5%
BlackRock Short-Term California Muni Bond ETF (NASDAQ:CALY – Get Free Report) was the target of a large increase in short...
Hyzon Motors Inc. (NASDAQ:HYZN) Short Interest Up 46.5% in September
Hyzon Motors Inc. (NASDAQ:HYZN – Get Free Report) was the recipient of a large increase in short interest in the...
New York Mortgage Trust, Inc. (NYMTM) to Issue Quarterly Dividend of $0.49 on October 15th
New York Mortgage Trust, Inc. (NASDAQ:NYMTM – Get Free Report) declared a quarterly dividend on Thursday, September 19th, Wall Street...
Pegasystems Inc. (NASDAQ:PEGA) Declares Quarterly Dividend of $0.03
Pegasystems Inc. (NASDAQ:PEGA – Get Free Report) declared a quarterly dividend on Friday, September 13th, Zacks reports. Shareholders of record...